The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.
Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury.
Synthetic peroxisome proliferator-activated receptor gamma (PPAR-gamma) ligands shown to induce adipocyte differentiation and increase insulin sensitivity, thiazolidinediones have recently been implicated as regulators of cellular inflammatory and ischemic responses. Thiazolidinediones inhibit the activity of a number of transcriptional factors, including nuclear factor-gammaB, activating protein 1, signal transducers and activated T cells, and early response gene 1 by either PPAR-gamma-dependent or -independent mechanisms. Recent experimental studies demonstrated a dramatic protection by thiazolidinediones against cardiac, gastrointestinal and lung injury after ischemia-reperfusion, in addition to a significant reduction in infiltrating neutrophils. These reports have hypothesized that the inhibition of neutrophil-mediated inflammation by thiazolidinediones is involved in the reduction of ischemia-reperfusion-induced tissue injury. Altogether, recent findings suggest that thiazolidinediones could represent a novel therapeutic approach to reducing or preventing reperfusion injury.[1]References
- Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury. Naito, Y., Yoshikawa, T. Drugs of today (Barcelona, Spain : 1998) (2004) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Use
